Clinical trials: Histological Type of Neoplasm
Prostatic Neoplasms, Adenocarcinoma
A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer
The purpose of this study is to determine the recommended Phase 2 dose(s) (RP2D[s]) of JNJ-69086420 in Part 1 (Dose Escalation), to determine safety and preliminary signs of clinical activity at the RP2D(s) in Part 2 (Dose…
- Trial name
- NCT04644770
- Testing
- JNJ-69086420, JNJ-78278343, Stereotactic body radiation therapy
- Where
- 11 sites in United States
- Volunteers
- 144 people
- Sponsor
- Janssen Research & Development, LLC
Pediatric Cataract, IOL Implantation
Myopia Progression Control Using Atropine 0.05% After Pediatric Cataract Surgery And Intraocular Lens Implantation Surgery
Myopic shift remains a debilitating and unpredictable adverse event following pediatric cataract surgery. While research exploring peripheral myopic defocus for post-cataract surgery myopia prevention shows promising results, the…
- Conditions
- Pediatric Cataract, IOL Implantation, Myopia Progression
- Trial name
- NCT07364370
- Testing
- Atropine Eye drops
- Where
- Egypt
- Volunteers
- 50 people
- Sponsor
- Cairo University
HIV, AIDS
HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT
Kaposi's sarcoma (KS)is the commonest malignancy associated with HIV/AIDS. Therapy for this cancer, which causes substantial morbidity, is suboptimal in resource poor settings.
- Conditions
- HIV, AIDS, Kaposi's Sarcoma, Human Herpesvirus 8
- Trial name
- KAART (NCT00380770)
- Testing
- Generic HAART Triomune : d4T, 3TC, NVP, Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
- Where
- South Africa
- Volunteers
- 112 people
- Sponsor
- University of KwaZulu
Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin
S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer
This phase II trial is studying how well imatinib mesylate works in treating patients with metastatic or unresectable Merkel cell cancer.
- Conditions
- Recurrent Neuroendocrine Carcinoma of the Skin, Stage II Neuroendocrine Carcinoma of the Skin, Stage III Neuroendocrine Carcinoma of the Skin
- Trial name
- NCT00068783
- Testing
- imatinib mesylate, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Graft Versus Host Disease, Leukemia
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
RATIONALE: Giving chemotherapy and total-body irradiation before a donor peripheral blood stem cell and donor natural killer cell transplant helps stop the growth of cancer and abnormal cells and helps stop the patient's immune…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00450983
- Testing
- muromonab-CD3, natural killer cell therapy, fludarabine phosphate
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Myeloid Malignancy, Myelodysplastic Syndromes
Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid Neoplasms
The purpose of this research study is to test the safety of a new three drug combination of navitoclax, decitabine, and venetoclax to treat advanced myeloid malignancies.
- Conditions
- Myeloid Malignancy, Myelodysplastic Syndromes, Myelofibrosis, Acute Myeloid Leukemia
- Trial name
- NCT05455294
- Testing
- Navitoclax, Venetoclax, Decitabine
- Where
- 3 sites in United States
- Volunteers
- 16 people
- Sponsor
- Jacqueline Garcia, MD
Hepatocellular Carcinoma (HCC)
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
This is a multicenter, retrospective study planned to enroll patients with unresectable hepatocellular carcinoma (uHCC) who received first-line donafenib combined with an anti-PD-1/L1 monoclonal antibody and either TACE or HAIC…
- Trial name
- NCT07724951
- Testing
- Donafeinib, Transcatheter arterial chemoembolization, PD-1 / PD-L1 monoclonal antibody
- Where
- 8 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai Zhongshan Hospital
Multiple Myeloma, Chronic Kidney Disease
Optimising Renal Outcome in Myeloma Renal Failure
The purpose of this study is to compare the effectiveness of bortezomib versus thalidomide in reducing free light chains in the blood of myeloma patients.
- Trial name
- OPTIMAL (NCT02424851)
- Testing
- Bortezomib, Thalidomide, Bendamustine
- Where
- 9 sites in United Kingdom
- Volunteers
- 31 people
- Sponsor
- Oxford University Hospitals NHS Trust
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Esophageal Squamous Cell Carcinoma, Chemoradiation
Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC
This clinical trial has two stages: phase II and phase III. Eligible patients will be randomized 1:1 to the two arms: paclitaxel plus cisplatin and cisplatin plus 5-fluorouracil.
- Trial name
- NCT03623737
- Testing
- neoadjuvant chemoradiation
- Where
- Taiwan
- Volunteers
- 248 people
- Sponsor
- National Taiwan University Hospital
Multiple Myeloma
BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT
This study is a open-label, single-center Phase 2 study to evaluate the efficacy and safety of BCMA CAR-T Cell Therapy in High-risk NDMM Patients With Positive MRD After First-line ASCT.
- Trial name
- NCT05846737
- Testing
- anti-BCMA CAR-T
- Where
- China
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Hodgkin Disease, Lymphoma, T-Cell, Peripheral
A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers
This clinical trial is studying lymphoma. Lymphoma is a cancer that starts in the blood cells that fight infection. There are several types of lymphoma.
- Conditions
- Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
- Trial name
- NCT06254495
- Testing
- PF-08046044/SGN-35C
- Where
- 33 sites in United States, Denmark and 4 more
- Volunteers
- 58 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Hematologic Cancer, Colon Cancer
Precision Physical Exercise for Personalized Onco-Hematology.
Physical exercise, particularly strength training, has become an effective strategy to improve physical function, muscle mass, and quality of life in cancer patients.
- Conditions
- Hematologic Cancer, Colon Cancer, Breast Cancer, Lymphoma
- Trial name
- PEPOH (NCT07286539)
- Testing
- Supervised Intervention, Home-based Intervention
- Volunteers
- 150 people
- Sponsor
- University of Salamanca
Papillary Thyroid Carcinoma
Multimodal Deep Learning for Lymph Node Metastasis in Thyroid Cancer
Papillary thyroid carcinoma (PTC) is the most common endocrine malignancy in clinical practice, accounting for approximately 85% of all thyroid malignancies.
- Trial name
- NCT07299318
- Testing
- not intervention
- Where
- China
- Volunteers
- 3,200 people
- Sponsor
- West China Hospital
Stage IV Melanoma, Stage III Melanoma
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of vaccine therapy in treating patients who have high-risk stage III or completely…
- Conditions
- Stage IV Melanoma, Stage III Melanoma, Recurrent Melanoma
- Trial name
- NCT00019890
- Testing
- dendritic cell-gp100-MART-1 antigen vaccine, sargramostim
- Sponsor
- National Cancer Institute (NCI)
Esophageal Squamous Cell Carcinoma (ESCC)
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
This is a phase 3, randomized, double-blind, placebo-controlled study to compare the efficacy and safety of tislelizumab (BGB-A317) versus placebo in combination with chemoradiotherapy in participants with localized esophageal…
- Trial name
- NCT03957590
- Testing
- Tislelizumab, Paclitaxel, Cisplatin
- Where
- 33 sites in China
- Volunteers
- 370 people
- Sponsor
- BeiGene
Leukemia
Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)
The goal of this clinical research study is to learn if sapacitabine given in combination with 2 standard drugs (cyclophosphamide and rituximab) can help to control CLL and SLL.
- Trial name
- NCT01253460
- Testing
- Cyclophosphamide, Rituximab, Sapacitabine
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- M.D. Anderson Cancer Center
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma
Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer
This phase I trial studies the side effects and best dose of pembrolizumab when given together with chemoradiotherapy or radiation therapy in treating patients with small cell lung cancer.
- Conditions
- Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
- Trial name
- NCT02402920
- Testing
- Carboplatin, Cisplatin, Etoposide
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- M.D. Anderson Cancer Center
Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor
Assessment of Retreatment With Lutathera® in Patients With New Progression of Intestinal Well-differenciated NET
In France, since the reimbursement of Lutathera®, this treatment is allowed for retreatment if patients still fulfill the criteria of its indication and 4 news cycles could be proposed.
- Conditions
- Neuroendocrine Tumors, Intestinal Well Differentiated Endocrine Tumor, Progressive Disease
- Trial name
- ReLUTH (NCT04954820)
- Testing
- Lutathera
- Where
- 28 sites in France
- Volunteers
- 146 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Prophylactic Application of Donor-derived TCM After Allogeneic HSCT
PACT is a non-randomized multicentre phase I/II study to evaluate the feasibility and safety of the prophylactic administration of donor derived TCM.
- Trial name
- PACT (NCT02758223)
- Testing
- TCM allogeneic humane central memory T cells, cryopreserved
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- Wuerzburg University Hospital